Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 8.98 0.03 (0.34%) Market Cap: 1.29 Bil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 81/100

Aurinia Pharmaceuticals Inc. - Special Call Transcript

Dec 05, 2019 / 01:30PM GMT
Release Date Price: $15 (+78.78%)
Operator

Greetings. And welcome to the Aurinia Pharmaceuticals AURORA clinical trials results conference. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mr. Glenn Schulman, Head of Investor Relations. Thank you. You may begin.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thanks, Dana, and good morning, everyone. Thanks for joining us as we take the time to review the top line efficacy and safety results from the AURORA Phase III clinical trial with voclosporin. Joining me on the call this morning from the Aurinia team are: Mr. Peter Greenleaf, President and CEO; and Dr. Neil Solomons, Chief Medical Officer. Last night, we issued a press release detailing the results, which are available on our website at www.auriniapharma.com, along with a 6-K that's being filed with the SEC.

I'd like to remind you that today's call is also being webcast live on Aurinia's Investor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot